The TRAIL Receptor Agonist Drozitumab Targets Basal B Triple Negative Breast Cancer Cells that Express Vimentin and Axl

PURPOSE: Previously, we found that GST-tagged tumor necrosis factor-related apoptosis inducing ligand (TRAIL) preferentially killed triple negative breast cancer (TNBC) cells with a mesenchymal phenotype by activating death receptor 5 (DR5). The purpose of this study was to explore the sensitivity o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res Treat
Main Authors: Dine, Jennifer L., O’Sullivan, Ciara C., Voeller, Donna, Greer, Yoshimi E., Chavez, Kathryn J., Conway, Catherine M., Sinclair, Sarah, Stone, Brandon, Amiri-Kordestani, Laleh, Merchant, Anand S., Hewitt, Stephen M., Steinberg, Seth M., Swain, Sandra M., Lipkowitz, Stanley
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4753803/
https://ncbi.nlm.nih.gov/pubmed/26759246
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-015-3673-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados